Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016112455 - HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE

Publication Number WO/2016/112455
Publication Date 21.07.2016
International Application No. PCT/CA2016/000008
International Filing Date 13.01.2016
IPC
C07D 249/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
A61K 31/4164 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 31/4192 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41921,2,3-Triazoles
A61K 31/495 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 51/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4164
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 31/4192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41921,2,3-Triazoles
A61K 31/5375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 51/0453
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
041Heterocyclic compounds
044having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
0453having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K 51/0459
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
041Heterocyclic compounds
044having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
0459having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Applicants
  • BRITISH COLUMBIA CANCER AGENCY BRANCH [CA]/[CA]
  • THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDUSTRY LIAISON OFFICE [CA]/[CA]
  • SADAR, Marianne, Dorothy [CA]/[CA] (US)
  • MAWJI, Nasrin, R. [CA]/[CA] (US)
  • BANUELOS, Carmen, Adriana [MX]/[CA] (US)
  • ANDERSEN, Raymond, John [CA]/[CA] (US)
  • FERNANDEZ, Javier, Garcia [ES]/[ES] (US)
  • JIAN, Kunzhong [CA]/[CA] (US)
Inventors
  • SADAR, Marianne, Dorothy
  • MAWJI, Nasrin, R.
  • BANUELOS, Carmen, Adriana
  • ANDERSEN, Raymond, John
  • FERNANDEZ, Javier, Garcia
  • JIAN, Kunzhong
Agents
  • DEETH WILLIAMS WALL LLP
Priority Data
62/102,71913.01.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
(FR) COMPOSÉS HÉTÉROCYCLIQUES POUR L'IMAGERIE ET LE TRAITEMENT DU CANCER ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
(FR)
Cette invention concerne des composés ayant une structure de Formule I : ou un sel pharmaceutiquement acceptable, un tautomère ou un stéréoisomère de ceux-ci, R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, et n3 étant tels que définis dans la présente. Les utilisations de ces composés pour moduler l'activité du récepteur des androgènes, imager des diagnostics dans le domaine du cancer et des substances thérapeutiques, et des méthodes destinées à traiter des sujets en ayant besoin, dont des sujets atteints du cancer de la prostate sont en outre décrits.
Latest bibliographic data on file with the International Bureau